Intravascular lithotripsy successfully treated resistant stent underexpansion, increasing minimal stent area from 2.71 to 6.44 mm2 (238% gain) with no 30-day major adverse cardiac events.
Case Report (n=13)
Yes
Does intravascular lithotripsy improve minimal stent area in patients with stent underexpansion resistant to conventional treatment?
Intravascular lithotripsy safely and effectively improves minimal stent area in patients with calcific coronary disease and stent underexpansion resistant to high-pressure balloon inflation.
Abstract Objectives This study aimed to present a case series of patient treated for stent underexpansion resistant to conventional treatment with intravascular lithotripsy (IVL). Background Stent underexpansion is a powerful predictor of long‐term stent patency and correlates with unfavorable clinical outcomes. This case series demonstrates the utility of IVL in managing stent underexpansion resistant to conventional treatment. Methods We describe a case series of patients with stent underexpansion due to calcific coronary artery disease treated with IVL. Stent underexpansion was identified as an inability to adequately expand stents with conventional treatment. Only cases that failed to achieve adequate expansion with high‐pressure noncompliant balloon inflation were included. Results Thirteen patients from six institutions have been included in this case series. The average age was 70.25 years with 76.9% of male patients. The average pre‐IVL minimal stent area (MSA) was 2.71 mm 2 , which improved to 6.44 mm 2 post‐IVL treatment, representing an average MSA gain of 238%. There were no procedural, peri‐procedural, or 30‐day major adverse cardiac and cerebrovascular event. Conclusion This case series demonstrates that IVL is a feasible, safe alternative for the management of stent underexpansion due to calcific coronary disease.
Yeoh et al. (Wed,) conducted a case report in Stent underexpansion due to calcific coronary artery disease (n=13). Intravascular lithotripsy (IVL) was evaluated on Minimal stent area (MSA) and 30-day major adverse cardiac and cerebrovascular events. Intravascular lithotripsy successfully treated resistant stent underexpansion, increasing minimal stent area from 2.71 to 6.44 mm2 (238% gain) with no 30-day major adverse cardiac events.